High-resolution transrectal ultrasound: Pilot study of a novel technique for imaging clinically localized prostate cancer by Pavlovich, Christian P. et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Uniformed Services University of the Health
Sciences U.S. Department of Defense
2014
High-resolution transrectal ultrasound: Pilot study
of a novel technique for imaging clinically localized
prostate cancer
Christian P. Pavlovich
Johns Hopkins Medical Institutions, cpav1ov2@jhmi.edu
Toby C. Cornish
Johns Hopkins Medical Institutions
Jeffrey K. Mullins
Johns Hopkins Medical Institutions
Joel Fradin
Johns Hopkins Medical Institutions
Lynda Z. Mettee
Johns Hopkins Medical Institutions
See next page for additional authors
Follow this and additional works at: https://digitalcommons.unl.edu/usuhs
This Article is brought to you for free and open access by the U.S. Department of Defense at DigitalCommons@University of Nebraska - Lincoln. It has
been accepted for inclusion in Uniformed Services University of the Health Sciences by an authorized administrator of DigitalCommons@University
of Nebraska - Lincoln.
Pavlovich, Christian P.; Cornish, Toby C.; Mullins, Jeffrey K.; Fradin, Joel; Mettee, Lynda Z.; Connor, Jason T.; Reese, Adam C.;
Askin, Frederic B. M.D; Luck, Rachael B.A.; Epstein, Jonathan I. M.D.; and Burke, Harry B. M.D., Ph.D., "High-resolution transrectal
ultrasound: Pilot study of a novel technique for imaging clinically localized prostate cancer" (2014). Uniformed Services University of the
Health Sciences. 159.
https://digitalcommons.unl.edu/usuhs/159
Authors
Christian P. Pavlovich; Toby C. Cornish; Jeffrey K. Mullins; Joel Fradin; Lynda Z. Mettee; Jason T. Connor;
Adam C. Reese; Frederic B. Askin M.D; Rachael Luck B.A.; Jonathan I. Epstein M.D.; and Harry B. Burke
M.D., Ph.D.
This article is available at DigitalCommons@University of Nebraska - Lincoln: https://digitalcommons.unl.edu/usuhs/159
ELSEVIER Urologic Oncology: Seminars and Original Investigations 32 (2014) 34.e27-34.e32 
Original article 
UROLOGIC 
ONCOLOGY 
High-resolution transrectal ultrasound: Pilot study of a novel technique for 
imaging clinically localized prostate cancer 
Christian P. Pavlovich, M.D.a,*, Toby C. Cornish, M.D., Ph.D.b, Jeffrey K. Mullins, M.D.a, 
Joel Fradin, M.D.c, Lynda Z. Mettee, P.A.-C.a, Jason T. Connor, Ph.D.d,e, 
Adam C. Reese, M.D.a, Frederic B. Askin, M.D.b, Rachael Luck, B.A.b, 
Jonathan 1. Epstein, M.D.a,b, Harry B. Burke, M.D., Ph.Df,g 
a James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD 
b Department of Pathology, Johns Hopkins Medical Institutions, Baltimore, MD 
C Russell H. Morgan Department of Radiology, Johns Hopkins Medical Institutions, Baltimore, MD 
d Berry Consultants, Orlando, FL 
e University of Central Florida College of Medicine, Orlando, FL 
f Biomedical Informatics Department, Uniformed Services University of Health Sciences, Bethesda, MD 
g Medicine Department, Uniformed Services University of Health Sciences, Bethesda, MD 
Received 8 November 2012; received in revised form 31 December 2012; accepted 19 January 2013 
Abstract 
Objectives: To detennine how high-resolution transrectal ultrasound (HiTRUS) compares with conventional TRUS (LoTRUS) for the 
visualization of prostate cancer. 
Methods and materials: Twenty-five men with known prostate cancer scheduled for radical prostatectomy were preoperatively imaged 
with both LoTRUS (5 MHz) and HiTRUS (21 MHz). Dynamic cine loops and still images for each modality were saved and subjected to 
blinded review by a radiologist looking for hypoechoic foci ~5 mm in each sextant of the prostate. Following prostatectomy, areas of 
prostate cancer ~ 5 mm on pathologic review were anatomically correlated to LoTRUS and HiTRUS findings. The accuracy of LoTRUS 
and HiTRUS to visualize prostate cancer in each sextant of the prostate and to identify high-grade and locally advanced disease was 
assessed. The McNemar test was used to compare sensitivity and specificity and paired dichotomous outcomes between imaging modalities. 
Results: Among 69 sextants with pathologically identified cancerous foci at radical prostatecomy, HiTRUS visualized 45 and missed 24, 
whereas LoTRUS visualized 26 and missed 43. Compared with LoTRUS, HiTRUS demonstrated improved sensitivity (65.2% vs. 37.7%) 
and specificity (71.6% vs. 65.4%). HiTRUS's agreement with pathologic findings was twice as high as LoTRUS (P = 0.006). HiTRUS 
provided a nonsignificant increase in visualization of high-grade lesions (84% vs. 60%, P = 0.11). 
Conclusions: HiTRUS appears promising for prostate cancer imaging. Our initial experience suggests superiority to LoTRUS for the 
visualization of cancerous foci, and supports proceeding with a clinical trial in the biopsy setting. © 2014 Elsevier Inc. All rights reserved. 
Keywords: Diagnosis; Prostate cancer; Radical prostatectomy; Ultrasound; Sensitivity and specificity 
1. Introduction 
Imaging modalities have fallen short of expectations for 
the detection of clinically localized prostate cancer. Despite 
advances in transrectal ultrasound (TRUS), computed 
tomography, and magnetic resonance imaging (MRI), the 
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majority of prostate cancers are detected through prostate-
specific antigen (PSA) screening or by digital rectal 
examination (DRE) or both. Dedicated prostate imaging is 
typically performed during prostate biopsy primarily as a 
guide to localizing the prostate for accurate needle place-
ment. Even in the face of known prostate cancer (active 
surveillance cohorts), it is often difficult to identify small, 
non-palpable lesions [1,2]. Enhanced ultrasound tech-
niques including color and power Doppler have been used 
in an attempt to enhance prostate cancer detection 
over conventional TRUS (LoTRUS). However, despite
modest improvements over LoTRUS these modalities
are not in widespread clinical use despite availability
[3–6].
Endorectal coil MRI and 3-T MRI are more recent
advances that are used primarily to localize and stage
known disease for the purposes of guiding therapy [7–9].
However, despite promising reports on their use in cancer
detection in at-risk populations [10,11], MRIs are not
routinely used to diagnose prostate cancer in the United
States. The radiologist expertise required for a precise
interpretation of multiparametric prostate MRI and stand-
ardization of the technique are among issues affecting
widespread adoption of this technology. There is clearly
room for urologist-performed, office-based prostate imag-
ing to better identify men with an elevated PSA or
abnormal DRE who should undergo a prostate biopsy,
and to perhaps target this biopsy more accurately. Ulti-
mately, enhanced urologist-performed prostate imaging in
conjunction with MRI may improve anatomic character-
ization of cancerous foci enough to decrease the number of
biopsies performed in both screening and surveillance
settings.
Given that TRUS is a standard part of the clinical
practice of every urologist that performs prostate biopsy
in the United States, where over 1 million prostate
biopsies are performed annually, it is of potentially great
benefit to improve upon this technology [12]. Conven-
tional prostate TRUS is typically performed at 5 to
9 MHz, frequencies that allow for adequate depth of
penetration and fair contrast between the prostate and
adjacent structures (bladder and seminal vesicles).
Although these low frequencies allow for adequate imag-
ing of the prostate in contrast to adjacent structures, they
are suboptimal in delineating intraprostatic architecture.
High-resolution (16–21 MHz) ultrasound probes have
been available for cutaneous and small animal imaging
for some time [13,14], but a high-resolution TRUS
(HiTRUS) probe for prostatic imaging was developed
only recently. This higher resolution equipment may
represent a needed advance in prostate cancer visual-
ization at the clinically localized stage, particularly in the
peripheral zone.
The present study was designed to determine how
HiTRUS compares with LoTRUS for visualizing prostate
cancer. Men who had known clinically localized prostate
cancer that were scheduled for radical prostatectomy were
recruited and offered LoTRUS as well as HiTRUS
preoperatively. Correlations were made between foci of
prostate cancer Z5 mm on pathologic analysis and the
locations of lesions Z5 mm in maximal diameter on
imaging. Pathologists were blinded to any imaging data,
and the interpreting radiologist was blinded to all patho-
logic data. The goal of the study was to define how
accurate either imaging modality was for identifying
prostate cancer foci Z5 mm.
2. Methods and materials
2.1. Study design
From 2010 to 2011, men with biopsy-proven prostate
cancer scheduled for robot-assisted radical prostatectomy
(RARP) who had a TRUS-determined volume o60 cc were
prospectively recruited into an institutional review board
and cancer committee-approved study. Patient recruitment
ended after the accrual goal of 25 patients was reached. All
patients scheduled for RARP during the study period were
offered participation in the study. Volume determination for
study inclusion was calculated at the time of diagnostic
prostate biopsy by a LoTRUS probe. No further inclusion
or exclusion criteria were applied.
After obtaining written informed consent, participating
men underwent LoTRUS and HiTRUS imaging in a single
setting prior to RARP. Dynamic cine loops and still images
were saved during each TRUS examination. All images and
cine loops were subsequently reviewed by a radiologist with
expertise in diagnostic ultrasonography (J.F.) to identify
areas of hypoechogenicity Z5 mm in any diameter within
each prostate sextant. The radiologist was aware that each
patient had prostate cancer but was blinded to clinical and
pathologic data, including cancer location, volume, grade,
and stage.
After RARP, actual areas of prostate cancer Z5 mm
were identified and localized within a prostate sextant(s).
Correlations between pathologic and ultrasound findings
were made sextant by sextant such that 6 specific areas of
each prostate were assessed for sonographic-pathologic
concordance—the right and left apex, mid, and base,
respectively, with the sextant areas extending up to the
anterior aspect of the prostate (Fig. 1). Ultrasound and
pathologic concordance was determined by consensus
opinion of reviewing physicians. Sensitivity and specificity
analysis for the identification of pathologically confirmed
cancerous foci was performed for each imaging modality.
The performance of HiTRUS in identifying these cancerous
foci was compared with LoTRUS.
Postprostatectomy pathologic data including prostate
size, Gleason score, and local tumor extent were recorded
for each patient. The ability of each imaging modality to
estimate prostate volume, identify high-grade disease (Glea-
son sum Z7), and identify locally advanced lesions (extrap-
rostatic extension) was assessed.
2.2. TRUS evaluation
LoTRUS and HiTRUS examinations were performed by
a single urologist (C.P.P.) with 410 years of experience
performing TRUS. All patients underwent DRE followed
by TRUS imaging that alternated in order—some under-
went HiTRUS first, others LoTRUS first. LoTRUS images
were obtained with a conventional 5-MHz end-fire trans-
ducer (Hitachi Aloka Medical, Ltd., Tokyo, Japan) and
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HiTRUS images were obtained with a 512 element,
21-MHz center-frequency side-fire transducer (Imagistx,
Inc., Las Vegas, NV). Dynamic cine loops and still images
were saved for both modalities in a standardized fashion
(1 right-to-left approximately 15-s entire prostate loop and
approximately 7 sagittal images for LoTRUS, and 3 to 5
approximately 5-s cine loops, an approximately 45-s entire
prostate loop, and approximately 7 sagittal images for
HiTRUS). Prostate volume was calculated using the for-
mula for an ellipsoid using 3 axes for LoTRUS (height,
width, and length, formula V ¼ [W  L  H]  p/6), and
using 2 axes (height and length and estimating the third for
HiTRUS [formula V ¼ {L  L  H}  p  1.108 
1.108/{6  1.025}]) for HiTRUS as this technique is, at
present, sagittal only.
2.3. Pathologic analysis
After RARP, men had their prostates sagittally sectioned
and then further sectioned into quadrants as per the
pathology department’s routine. All specimens were proc-
essed by a single histopathologic assistant (R.L.) and the
cases were initially evaluated for diagnosis by a single
pathologist (F.A.) who was blinded to imaging data.
Resulting glass slides were digitized using an iScan
Coreo Au (Ventana Medical System, Inc., Tucson, AZ)
slide scanner. An expert anatomic pathologist (T.C.C.)
annotated digital images with freehand drawing tools in
ImageJ (National Institutes of Health, Bethesda, MD) using
a Cintiq 21UX LCD graphics tablet (Wacom Co., Ltd.,
Vancouver, WA). All foci of prostate cancer were included
in the annotation process, and a leading expert reviewed
foci in which the diagnosis was uncertain (J.I.E.). The
annotated digital images of the sagittal quadrants were then
fitted together manually to create seamless (mosaic), digi-
tally reconstructed whole-mount sections.
2.4. Statistical analysis
The McNemar test was used to compare sensitivity and
specificity between LoTRUS and HiTRUS for detection of
cancers Z5 mm using the excised prostate specimen sec-
tions as the reference. Additionally, the McNemar test was
used to compare paired dichotomous outcomes between
LoTRUS and HiTRUS. The standards for the reporting of
diagnostic accuracy (STARD) guidelines were observed
when reporting results. Analyses were performed using
STATA version 11.0 (Stata Corp LP, College Station, TX)
and R 2.14.1 (The R Foundation for Statistical Computing,
Vienna, Austria).
3. Results
3.1. Patients
A total of 25 men underwent LoTRUS and HiTRUS
followed by RARP. Demographic, clinical, and pathologic
data are listed in Table 1. No complications or adverse
events occurred during preoperative imaging or RARP.
Average estimated prostate volume was 27.3 cc with
LoTRUS and 26.6 cc with HiTRUS. Average pathologic
Fig. 1. (A) Reconstructed sagittal prostate section with Gleason 3 þ 4 ¼ 7
tumor at left apex outlined in green ink. This corresponds to a hypoechoic
lesion most accurately identified on high-resolution transrectal ultrasound
(B). The lesion is less clearly defined on low-resolution transrectal
ultrasound and could be missed (C). (Color version of figure is available
online.)
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specimen weight was 44.9 g. The mean discrepancy
between estimated prostate volume and actual pathologic
volume was 17.6 cc (0.7–33.8) for LoTRUS and 18.3 cc
(5.8–34.8) for HiTRUS (P ¼ 0.80), largely due to seminal
vesicle weight.
3.2. Identification of prostate cancer
Cancerous fociZ5 mm were identified within 69 pros-
tate sextants. LoTRUS identified 26 and missed 43 sextants
with cancer foci (38% correct). HiTRUS identified 45 and
missed 24 sextants with cancerous foci (65% correct).
Benign tissue was incorrectly identified as a cancerous
focus within 28 and 23 sextants using LoTRUS and
HiTRUS, respectively. Compared with LoTRUS, HiTRUS
had higher sensitivity, specificity, positive predictive value,
and negative predictive value (Table 2).
In 37.3% of sextants both LoTRUS and HiTRUS were
concordant with pathology, and in 16% neither was con-
cordant with pathology. In the 46.7% of sextants where
LoTRUS and HiTRUS were not in agreement, LoTRUS
and HiTRUS were concordant with pathology in 32.9% and
67.1%, respectively. HiTRUS’s agreement with pathologic
findings was twice as high as that of LoTRUS (P ¼ 0.006).
3.3. Identification of high-grade and locally advanced
disease
Pathologic review of the reconstructed digital whole-
mount radical prostatectomy specimens demonstrated 43
discrete cancerous lesionsZ5 mm. There were fewer dis-
crete cancerous lesions compared with the number of prostate
sextants harboring cancer given that several lesions invol-
vedZ1 sextant. Final pathologic grade was Gleason 3þ 3 ¼
6, 3 þ 4 ¼ 7, and 4 þ 3 ¼ 7 in 18, 17, and 8 lesions,
respectively. Extraprostatic extension was identified in 6
patients. In total, HiTRUS identified significantly more of
the cancerous lesions than LoTRUS (79.1% vs. 51.2%,
Po 0.008). Furthermore, HiTRUS identified more high-
grade (primary or secondary Gleason pattern Z4) lesions
than LoTRUS, though this did not reach statistical signifi-
cance (84% vs. 60%, P ¼ 0.11). HiTRUS and LoTRUS
each identified 66.7% of lesions with extraprostatic exten-
sion, though seminal vesicle invasion was not specifically
evaluated (Table 3).
4. Discussion
Despite numerous advances in prostate cancer imaging
over the past 35 years, the ability to reliably image cancer-
ous foci within the prostate remains limited. Hindered by
suboptimal sensitivity, few advances in imaging technology
have achieved widespread acceptance by the urologic
community. Thus, LoTRUS-guided, systematic prostate
biopsy remains the predominant means for identifying
prostate cancer in men with an elevated PSA or abnormal
DRE or both in the United States.
In the present study, we present the first clinical applica-
tion of a novel 512 element, 21-MHz center-frequency
sagittal transducer probe to human prostate cancer. The trans-
ducer probe and technology were easy to use for the clinician
and well tolerated by patients. Enhanced visualization of
intraprostatic architecture resulted in improved detection of
significant cancerous foci compared with LoTRUS in a blin-
ded, randomized comparison. As expected, despite improved
Table 1
Demographic, clinical, and pathologic data of 25 men with clinically
localized prostate cancer undergoing high-resolution and low-resolution
(conventional) transrectal ultrasound followed by robot-assisted radical
prostatectomy
Variable Median (range) or % (n)
Clinical and demographic data
Age 59 (50–70)
Race
Caucasian 84% (21)
African American 12% (3)
Other 4% (1)
PSA, ng/dL 5.5 (2.5–9.9)
Clinical stage
T1c 84% (21)
T2a 8% (2)
T2b 8% (2)
Biopsy Gleason score
3 þ 3 ¼ 6 12% (3)
3 þ 4 ¼ 7 64% (16)
4 þ 3 ¼ 7 16% (4)
8–10 8% (2)
Pathologic data
Prostate and seminal vesicles weight, g 44.4 (23.5–66)
Pathologic Gleason score
3 þ 3 ¼ 6 28% (7)
3 þ 4 ¼ 7 48% (12)
4 þ 3 ¼ 7 24% (6)
Pathologic Stage
T2 76% (19)
T3a 12% (3)
T3b 12% (3)
Table 2
Comparison of low-resolution (conventional) transrectal ultrasound
(LoTRUS) and high-resolution transrectal ultrasound (HiTRUS) in the
identification of pathologic cancerous fociZ5 mm detected upon review of
complete radical prostatectomy specimens
Sensitivity, % Specificity, % PPV, %a NPV, %b
LoTRUS 37.7 65.4 48.1 55.2
HiTRUS 65.2 71.6 66.2 70.7
aPositive predictive value.
bNegative predictive value.
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cancer detection, there were false-negative and false-positive
results with HiTRUS. This was expected given the novelty of
HiTRUS to both the radiologist and urologist involved in the
study, the first-generation nature of the probe and imaging
station, the lack of any image enhancement techniques such
as Doppler flow, and perhaps limitations inherent to ultra-
sound imaging of prostate cancer. These data should not be
interpreted to suggest that HiTRUS replace biopsy for
prostate cancer detection, but rather that HiTRUS may be
superior to LoTRUS and warrants further investigation, such
as for targeting prostate biopsies or cancer monitoring or both
in active surveillance populations.
Since its introduction in the 1970s, TRUS-guided prostate
biopsy has become the gold standard in the diagnosis of
prostate cancer [15]. Unfortunately, at standard low reso-
lutions, the similarly echogenic properties of cancerous foci
and noncancerous prostate tissue have limited the ability of
TRUS to be used as a singular modality in cancer diagnosis.
In fact, up to 40% of cancerous foci are isoechoic to
surrounding benign tissue on LoTRUS [16–18]. Therefore,
since Hodge’s comparison study in 1989, systematic rather
than targeted biopsies have remained the standard in prostate
cancer detection [19–21].
Discovery of capillary neovascularization and increased
microvessel density within prostate cancer lesions has led
to new modalities of ultrasonography [22]. Color and
power Doppler were introduced to detect increased vascu-
larity within the prostate that may correlate with prostate
cancer [3,4,23,24]. More recently, microbubble-enhanced
Doppler TRUS has shown improvement over unenhanced
LoTRUS in identifying prostate cancer foci [25–28].
However, mixed reports on the utility of such technolo-
gies, and modest improvements demonstrated in cancer
detection over unenhanced LoTRUS have limited their
widespread adoption. Furthermore, increased costs of
technology, prolonged examination times, and variability
in interpretation of ultrasound results have further hindered
dissemination of these advances into routine urologic
practice. HiTRUS represents a readily adoptable technol-
ogy that was well tolerated by patients, and shows
significant promise in visualizing cancerous foci in real
time without exposing patients to prolonged examinations
or injectable agents.
This pilot study was specifically designed to provide an
initial assessment of the potential utility of a new technol-
ogy to image prostate cancer in the clinically localized
setting. As such, it was subject to many limitations. Prostate
imaging by HiTRUS had not previously been performed by
any study investigator, hence the preliminary nature of the
data collected. Additionally, ultrasound images and
dynamic cine loops for both HiTRUS and LoTRUS were
reviewed after TRUS and not in real time by the blinded
study radiologist. Although real-time evaluation is acknowl-
edged to be optimal for ultrasonic evaluations in general,
this would be unlikely to have introduced bias into the
study given that it affected both modalities equally. This
study was performed on only 25 patients because of cost
and manpower limitations, given how exhaustive the digital
reconstruction and pathologic analysis of whole-mount
prostates was for purposes of direct comparison with
sagittal ultrasound examinations, and preliminary nature
of the imaging technology. This pilot study was specifically
designed to assess for the presence of small lesions in men
with known prostate cancer. The lesion target size threshold
decided upon (0.5 cm diameter) was well below an accepted
threshold for clinically significant prostate cancer (1 cm
diameter, 0.5 cc volume) so as to garner as much informa-
tion as possible pertaining to this new technology. How-
ever, because of post–pathologic processing volume loss
some lesions meeting the size criteria may have been
overlooked. No conclusions can be made regarding the
utility of HiTRUS in the screening/biopsy setting at this
time; however, HiTRUS has demonstrated significant
promise in terms of identifying small hypoechogenic foci
that proved cancerous at radical prostatectomy. The utility
of this technology, which trades more limited depth of
penetration in exchange for better resolution in the
peripheral zone, to identify anterior tumors in larger
glands or seminal vesicle invasion still needs to be
determined—to date only glands o60 g were imaged
[29]. In fact, of the 8 anterior tumors present in our pilot
study, HiTRUS identified 1 and LoTRUS did not visual-
ize any of these lesions. Finally, only echogenicity was
used to assess the ultrasound images. It is anticipated that
additional image features such as Doppler might inform
future studies.
Table 3
Comparative analysis of low-resolution (conventional) transrectal ultrasound (LoTRUS)and high-resolution transrectal ultrasound (HiTRUS) in identifying
high-grade (any Gleason patternZ4), low-grade (Gleason 3 þ 3 ¼ 6), and locally advanced (presence of extraprostatic extension) prostate cancer. Lesions
characterized upon pathologic analysis of complete radical prostatectomy specimens
Variable Pathologic lesions LoTRUS HiTRUS P-value
Total lesions 43 22 (51.2%) 34 (79.1%) 0.008
Dominant lesiona 25 15 (60%) 20 (80%) 0.23
High-grade lesion 25 15 (60%) 21 (84%) 0.11
Low-grade lesion 18 7 (38.9%) 13 (72.2%) 0.15
Lesions with extraprostatic extension 6 4 (66.7%) 4 (66.7%) –
aThe largest lesion identified upon analysis of radical prostatectomy specimen.
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Imaging the prostate with sufficient accuracy to identify
prostate cancer has long been an elusive goal. HiTRUS
provides better resolution of the prostatic peripheral zone
and significantly improves the visualization of prostate
cancer foci, at the expense of more limited penetration.
These promising results justify the refinement and study of
HiTRUS, and its assessment on a larger scale in the
screening/biopsy setting.
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